3/1/2012

Duke Translational Medicine Institute and Bristol-Myers Squibb announced a collaborative deal to develop a treatment for idiopathic pulmonary fibrosis. Longer-term goals include moving new drug candidates into proof-of-concept trials, boosting enrollment in clinical trials and developing disease education programs.

Related Summaries